Placebo to AIN457 300 mg/2 mL Solution for injection in pre-filled syringe, Cosentyx 300 mg solution for injection in pre-filled syringe
CAIN457R1DE01
Phase 3 small_molecule active
Quick answer
Placebo to AIN457 300 mg/2 mL Solution for injection in pre-filled syringe, Cosentyx 300 mg solution for injection in pre-filled syringe for Giant Cell Arteritis is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Giant Cell Arteritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active